Evidence Based Management of Herpes Zoster Ophthalmicus by Buckmier, Mikkel, RN
University of North Dakota 
UND Scholarly Commons 
Nursing Capstones Department of Nursing 
Spring 5-1-2020 
Evidence Based Management of Herpes Zoster Ophthalmicus 
Mikkel Buckmier RN 
mikkel.buckmier@und.edu 
Follow this and additional works at: https://commons.und.edu/nurs-capstones 
 Part of the Nursing Commons 
Recommended Citation 
Buckmier, Mikkel RN, "Evidence Based Management of Herpes Zoster Ophthalmicus" (2020). Nursing 
Capstones. 294. 
https://commons.und.edu/nurs-capstones/294 
This Independent Study is brought to you for free and open access by the Department of Nursing at UND Scholarly 
Commons. It has been accepted for inclusion in Nursing Capstones by an authorized administrator of UND 
Scholarly Commons. For more information, please contact und.commons@library.und.edu. 








Evidence Based Management of Herpes Zoster Ophthalmicus 
Mikkel Buckmier 
Master of Science in Nursing – Family Nurse Practitioner 
University of North Dakota 
Spring 2020 
  
MANAGEMENT OF HERPES ZOSTER OPHTHALMICUS 2 
PERMISSION 
 
Title:  Evidence Based Management of Herpes Zoster Ophthalmicus 
Department:  Nursing 
Degree:  Master of Science 
 
In presenting this independent study in partial fulfillment of the requirements for a graduate 
degree from the University of North Dakota, I agree that the College of Nursing & Professional 
Disciplines of this University shall make it freely available for inspection. I further agree that 
permission for extensive copying or electronic access for scholarly purposes may be granted by 
the professor who supervised my independent study work or, in his/her absence, by the 
chairperson of the department or the dean of the Graduate School. It is understood that any 
copying or publication or other use of this independent study or part thereof for financial gain 
shall not be allowed without my written permission. It is also understood that due recognition 
shall be given to me and to the University of North Dakota in any scholarly use which may be 





   Signature:  Mikkel Buckmier   
 
 




MANAGEMENT OF HERPES ZOSTER OPHTHALMICUS 3 
Abstract 
 This literature review was conducted based upon the successful completion of an 
Objective Structured Clinical Examination (OSCE) and oral defense, under the supervision of a 
program instructor. The case report was analyzed and the topic of effective management of 
herpes zoster ophthalmicus was developed. Research was conducted through the databases 
CINAHL and PubMed. Limits were applied to every search, including only articles within the 
last 5 years and articles available in full text. The reference lists of relevant articles were also 
reviewed for further pertinent articles with useful research. A total of twelve research articles 
were used for the purpose of this literature review. 
 Herpes zoster ophthalmicus (HZO) is a debilitating dermatomal rash that affects the V1 
ophthalmic region of the face, unilaterally affecting the forehead, upper eyelid, and nose. HZO 
poses a risk for severe ocular complications, as it can affect any structure of the eye through the 
nerve pathways. This can lead to long term ocular complications, including vision loss. This 
literature review identifies proper antiviral treatment to reduce associated complications, timely 
treatment, steroid use, and additional self-management. It additionally addresses the importance 
of an ophthalmology referral for thorough assessment and proper treatment of ocular 
complications. Implementing evidence-based management of HZO provides the patient with the 
best potential outcome of this complicated disease process. 
Keywords: herpes zoster ophthalmicus, management, treatment, ocular complications  
MANAGEMENT OF HERPES ZOSTER OPHTHALMICUS 4 
Background 
 Herpes zoster, also known as shingles, is a painful vesicular rash that appears in about 
33% of people in the United States in their lifetime (Freund & Chen, 2018). Pain, itching, or 
tingling often precede the appearance of the rash, followed by the appearance of little blisters 
that will rupture and turn into scabs within the next seven to ten days (CDC, 2019). Associated 
symptoms include fever, headache, chills, and/or upset stomach (CDC, 2019). As age increases, 
so does the risk of developing shingles, as well as the risk for complications associated with 
shingles (CDC, 2019). About 10-18% of people will develop postherpetic neuralgia, the nerve 
pain associated with shingles and the most common complication of shingles that can last for 
months to years following the resolution of the rash (CDC, 2019).  
Those who have a history of chicken pox, which is about 99% of people born before 
1980, are at risk for developing shingles (CDC, 2019). Varicella zoster virus is the chickenpox 
virus that lays dormant after infection, and years later may reactivate as herpes zoster to cause 
shingles (CDC, 2019). It spreads through direct contact with the fluid-filled blisters of the herpes 
zoster rash (CDC, 2019). Furthermore, it is only infectious when the blisters are present or 
weeping (CDC, 2019). Herpes zoster can cause chickenpox in an adult or child who does not 
have immunity to chickenpox, either through history or vaccine, but it cannot cause another 
person to develop shingles (CDC, 2019). There are two vaccines in the United States for 
prevention of shingles in those over age 50: zoster vaccine live (Zostavax) and recombinant 
zoster vaccine (Shingrix) (CDC, 2019; Li, 2018). Zostavax has a prevention rate of 51% since 
2006, whereas Shingrix is more effective at up to 97% prevention since it was released in 2017 
(Freudn & Chen, 2018; CDC, 2019; Li, 2018). 
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The risk for complications increases if the rash is on a person’s face, specifically around 
or near the eye – known as herpes zoster ophthalmicus (HZO). Approximately 10-20% of all 
herpes zoster cases are diagnosed as herpes zoster ophthalmicus (HZO) with 50% experiencing 
ocular involvement (Freund & Chen, 2018). Complications of HZO due to ocular involvement 
can threaten vision and require urgent assessment by an ophthalmologist, including symptoms 
such as decreased vision, redness or pain in the eye, or neurologic symptoms (Freund & Chen, 
2018). The goals of HZO management are simply stated: shorten the course, pain relief, and 
prevent complications (Johnson, Amzat, & Martin, 2015). This paper explores the evidence-
based management of herpes zoster ophthalmicus in order to reduce and prevent associated 
complications.  
PICO QUESTION: In adult patients presenting to the primary care setting with herpes zoster 
ophthalmicus, what are the evidence-based guidelines for optimal management of the condition? 
Case Report 
 The following report is a novel case developed for the purpose of this evidence-based 
literature review. 
Chief Complaint: A healthy 70-year-old female presented to the clinic complaining of right eye 
pain and rash. 
HPI: The patient’s rash started two days prior, when she woke up in the morning. The rash was 
located above her right eyebrow, on her right eyelid, and followed along the right side of her 
nose. She described the pain as “on and off,” itchy and burning. It was aggravated by touch and 
laying down at night on her pillow. She denied radiating pain. For relief, the patient tried using 
Tylenol and ice, with little improvement. She rated her pain at 6/10.  
Past Medical History:  
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1. Essential hypertension 
2. Rheumatoid arthritis 
Past Surgical History: 
1. Hysterectomy 
Medications: 
1. Lisinopril 20mg PO daily 
2. Prednisone 10mg PO daily PRN  
3. Tylenol 650mg PO q6h PRN 
Allergies: NKA 
Social History: Widowed x 5 years, retired nurse x 8 years. Patient lives at home alone. She 
denied current or history of tobacco use. She did admit to alcohol use only on special occasions. 
For exercise, the patient likes to walk 20 minutes daily. 
Review of Systems: The patient admitted to recent blurring vision in the right eye, sharp pain in 
the right eye, and occasional photophobia in the right eye. She denied similar symptoms in the 
left eye. She had a burning pain and erythematous rash on the right side of her forehead, right 
upper eyelid, and along the right side of her nose. Patient also reported associated fatigue and 
headaches. She denied fever, nausea, vomiting, and generalized myalgias.  
Physical Exam: Vital signs: BP 154/90, pulse 78, temp 99.1˚F, respirations 18, O2 96%. She 
weighed 148 pounds and measured at 5’7” tall. Physical exam revealed a scattered vesicular rash 
on her forehead above her right eyebrow, upper right eyelid, and along the right side of her nose 
down to the tip of the nose (+Hutchinson sign). The vesicles were clear, grouped in different 
areas, with an erythematous base. The rash appeared to follow the V1 ophthalmic dermatome of 
the trigeminal nerve, unilaterally on the right side. Patient was tender upon palpation. 
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Ophthalmologic exam revealed irritation to right conjunctiva, some redness without drainage. 
PERRLA, EOM’s intact. Cranial nerves III-XII grossly intact, with a deficit in CN II as follows. 
Visual acuity 20/20 in the left eye, 20/50 in the right, and 20/20 when using both eyes together. 
Patient does not use contact lenses, and only uses reading glasses at home. Fundoscopic exam 
was normal in bilateral eyes. The remaining physical exam was unremarkable. 
Plan: The patient was diagnosed with herpes zoster ophthalmicus. Since it has been less than 72 
hours since the rash first appeared, the patient was treated with an antiviral to help reduce 
symptoms and prevent associated complications. She was given valacyclovir 1000mg PO q8h x 
7 days. An urgent referral was placed to ophthalmology for evaluation and management of 
ocular involvement. Patient was instructed to use Tylenol as needed for pain relief. She may try 
cold compresses to the rash for relief of pain and irritation. Patient to avoid excess exposure to 
heat, such as hot showers as this may aggravate the rash. Patient was educated on avoiding 
contact with children, pregnant individuals and immunocompromised individuals, as she may 
spread the varicella virus causing chicken pox. She should avoid touching the rash and practice 
good hand hygiene. Patient was told to follow up in 1 week for reevaluation of the rash in clinic, 
and follow up as instructed by ophthalmology. Patient was in agreeance with the plan of care, 
and had no further questions at that time. 
Literature Review 
Intro 
 This literature review seeks to identify the best practice for management of herpes zoster 
ophthalmicus for the purpose of the novel case report on the 70-year-old female patient. As 50% 
of cases of herpes zoster ophthalmicus (HZO) have ocular involvement, an accurate diagnosis is 
essential for proper assessment, follow up and treatment (Freund & Chen, 2018). A positive 
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Hutchinson sign, or finding of the herpes zoster rash on the tip of the nose, is strongly correlated 
with ocular involvement from HZO (Vrcek, Choudhury, & Durairaj, 2016). HZO usually 
presents as a dermatomal rash in V1: including the frontal, lacrimal, and nasociliary branches 
(Davis & Sheppard, 2019). The frontal branch has the supratrochlear and supraorbital sub-
branches, which innervate the skin of the upper eyelid, forehead, and central scalp (Davis & 
Sheppard, 2019). The lacrimal branch innervates the lacrimal gland, lateral upper eyelid, and 
lateral conjunctiva of the upper eyelid (Davis & Sheppard, 2019). Lastly, the nasociliary branch 
has multiple sub-branches that supply the pathway for the varicella virus to access the eye, as 
well as the external nasal nerve to the tip of the nose (Davis & Sheppard, 2019). Other 
manifestations include the typical vesicular rash of herpes zoster, burning, tingling, or shooting 
pain in one dermatome, and may be accompanied by fatigue, fever, headache, etc. (Vrcek, et al., 
2016). Aggressive treatment of herpes zoster ophthalmicus is essential to reduce the duration and 
severity of the acute infection, as well as prevent postherpetic neuralgia and significant visual 
impairment associated with HZO (Schuster, et al., 2016). Treatment of HZO is varied among 
providers, and different trials have reported different efficacies among therapy alternatives.  
Treatment - Antivirals 
Based upon many randomized control trials, antivirals are the mainstay of treatment for 
acute herpes zoster and HZO and are approved by the FDA (Lo, Jeng, Gillespie, Wu, & Cohen, 
2019). There are three commonly used antiviral agents to prevent the replication of the virus, 
varying in cost and convenience: Valacyclovir (1g PO TID x 7 days), famciclovir (500mg PO 
TID x 7 days), or acyclovir (800mg PO 5x/day x 7 days) (Fruend & Chen, 2018; Schuster, et al., 
2016; Li, 2018). Lo et al. (2019) identified the current practice patterns of providers for 
management of HZO. The majority of respondents (45.5%) used topical steroids and high dose 
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antivirals for acute HZO associated keratitis, while 23.6% using low dose antivirals and topical 
steroids (Lo, et al., 2019). In this study, valacyclovir 1,000mg was the most frequent used 
antiviral due to provider preference (Lo, et al., 2019). 
Schuster, et al. (2016) conducted a large study comparing valacyclovir versus acyclovir, 
evaluating the efficacy of its treatment in HZO. They compared ocular involvement, dendritic 
ulcers, uveitis, pain at 24 weeks, and adverse effects between the two antivirals (Schuster, et al., 
2016). Valacyclovir is an altered drug of acyclovir, in which it is converted to acyclovir after PO 
administration (Schuster, et al., 2016). This mechanism allows for increased plasma 
concentration of acyclovir, without the inconvenience of taking acyclovir five times per day with 
a lower plasma concentration due to first-pass metabolism (Schuster, et al., 2016). The study 
hypothesized that valacyclovir is likely equal in efficacy to IV acyclovir, and might be more 
efficacious than oral acyclovir (Schuster, et al., 2016). They concluded that the evidence in this 
one study is similar between the oral antivirals, and therefore inconclusive (Schuster, et al., 
2016). However, patient compliance may be greater with valacyclovir’s TID dose frequency, and 
the greater bioavailability of valacyclovir is an important consideration (Schuster, at al., 2016).  
Another study found valacyclovir to shorten duration of herpes zoster associated pain as 
well as duration of postherpetic neuralgia, compared to acyclovir (Li, 2018). On the other hand, a 
following study determined that the results were similar between the antivirals, and the findings 
in the earlier study were not supported (Li, 2018). Multiple studies have identified that there is 
no statistical significance among valacyclovir vs. acyclovir, or famciclovir vs. acyclovir 
(Werner, et al., 2017). Li found that “valacyclovir and acyclovir also appear to have a similar 
effect in prevention of ocular complications in HZO” (2018, p.331). Werner et al. (2017) 
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identified a randomized control trial that showed the benefit of systemic acyclovir over topical 
acyclovir for the ocular complications associated with HZO.  
In regards to time, antiviral therapy can significantly reduce the risk of complications in 
HZO if they are started within 72 hours of the onset of herpes zoster (Catron & Hern, 2008; 
Werner, et al., 2017; Johnson, et al., 2015). Reduction in acute pain, decreased risk of 
postherpetic neuralgia, improved healing of the lesions, decreased viral shedding, and decreased 
ocular involvement are all associated with prompt treatment with antivirals within the 72 hour 
window (Catron & Hern, 2008). No evidence has been shown in initiating therapy after this time 
frame, however many providers will still prescribe for 7-10 days after the onset of symptoms as 
the adverse effect profile of the antivirals are very low (Werner, et al., 2017; Johnson, et al., 
2015; Catron & Hern, 2008). Werner et al. (2017) states expert panels recommend initiation of 
antiviral therapy after the 72 hour timeframe if new vesicles are still appearing with a 
complicated course of shingles, such as in patients with cutaneous, visceral or neurological 
dissemination, in patients with HZ ophthalmicus or HZ oticus, as well as in all 
immunocompromised patients.  
A strong recommendation is also made for local acyclovir 3% ocular ointment to the 
HZO affected eye 5x/day (Werner, et al., 2017). Varicella DNA has been found to remain in the 
cornea for up to one month in the elderly and immunocompromised, for whom extending oral 
antiviral therapy beyond 7-10 days may also be beneficial, or with severe complications 
considering IV therapy (Vrcek, Choudhury, & Durairaj, 2016; Johnson, et al., 2015). IV antiviral 
therapy is indicated for patients with high risk cases of HZO, including but not limited to: 
immunodeficiency, patients on immunosuppressive medications, multiple dermatomes affected 
by herpes zoster, retinal involvement, corneal ulceration, or severe bacterial superinfection 
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(Catron & Hern, 2008). As one can see, a thorough understanding of potential ocular 
complications related to HZO and available treatment options are necessary to determine the 
proper course of antiviral treatment, which can be effectively determined and managed by 
ophthalmology.  
Treatment - Steroids 
Topical corticosteroids can be used to decrease inflammation and reduce ocular 
complications (Ahmad, Suan, & Alexander, 2019). Systemic corticosteroids, such as PO 
prednisolone or IV methylprednisolone, can be used in cases of “acute-phase pain, debilitating 
rash, facial palsy or cranial polyneuritis, and severe inflammatory ocular complications” 
(Ahmad, et al., 2019, p.99). Oral corticosteroids are recommended in conjunction with the 
antiviral medication to reduce the acute pain associated with HZO, as well as improve skin 
healing time (Vrcek, et al., 2016; Catron & Hern, 2008). Ophthalmic steroids, only prescribed in 
direct consultation with ophthalmology, can be beneficial for some ocular complications, such as 
stromal keratitis, uveitis, and scleritis (Vrcek, et al., 2016). However, these topical steroids can 
improve some ocular conditions and exacerbate others, so cautious prescribing is necessary 
(Johnson, et al., 2015). Steroids may be beneficial in HZO complications such as uveitis or 
scleritis, however steroid use should be avoided in epithelial keratitis, as well as patients with 
diabetes mellitus or gastritis (Johnson, et al., 2015). 
Ophthalmology Referral 
 Because there are many severe ocular complications associated with herpes zoster 
ophthalmicus, “early involvement of an ophthalmologist can be useful in avoiding vision-
threatening sequelae” (Vrcek, et al., 2016, p.22). Recommended physical exam of the eye 
includes “external inspection, visual acuity, visual fields, extra ocular movements, pupillary 
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response, fundoscopy, intraocular pressure, anterior chamber slit lamp exam, and corneal exam 
with and without staining” (Catron & Hern, 2008, p.175). Due to limited availability of these 
ophthalmologic resources in the primary care setting, referral to ophthalmology for a complete 
exam is necessary. This is especially important for HZO patients presenting with a decrease in 
vision or a red eye (Catron & Hern, 2008). “All patients with the possible diagnosis of HZO 
require ophthalmologic consultation […] in order to ensure full evaluation for serious 
complications” (Catron & Hern, 2008, p.176). After consultation, early ophthalmology follow up 
is important for continued monitoring and management of the disease process and associated 
complications (Catron & Hern, 2008). 
The viral replication can follow the nerves, causing inflammation that can affect multiple 
structures of the eye, including: the cornea, sclera, conjunctiva, iris, retina, and/or optic nerve 
(Vrcek, et al., 2016). If the nasociliary nerve is affected by HZO, the rash will appear on the tip 
of the nose: a positive Hutchinson sign (Li, 2018). Likewise, the nasociliary nerve also involves 
the cornea, conjunctiva, sclera and uvea – hence the association of a positive Hutchinson sign 
with HZO ocular involvement (Li, 2018). Ocular involvement can range from a cutaneous rash 
of the eyelid, to retinal disease leading to permanent vision damage (Vrcek, et al., 2016). As 
there is a strong correlation between herpes zoster ophthalmicus and ocular involvement, 
consultation with and an urgent referral to ophthalmology are recommended (Vrcek, et al., 
2016). 
Associated Ocular Complications 
Associated complications of herpes zoster ophthalmicus include “conjunctivitis, keratitis, 
iritis/uveitis, episcleritis/scleritis, extraocular motor nerve palsies, retinal perivasculitis and 
necrosis, and optic neuritis. The most common ocular findings of HZO are conjunctivitis seen in 
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35-70% of patients, uveitis in 18-47%, and keratitis in 13-75%” (Li, 2018, p.329). Artificial tears 
and erythromycin ophthalmic ointment may be recommended to keep the eye moist and prevent 
superinfection, such as in conjunctivitis (Vrcek, et al., 2016). 
For HZO with keratitis, endotheliitis, or anterior uveitis, topical ophthalmic steroids are 
recommended to be implemented by ophthalmology management, as significant ocular adverse 
effects - such as cataracts and steroid-induced glaucoma - may occur (Werner, et al., 2017; Li, 
2018). When using topical ophthalmic corticosteroids, a provider should prescribe the lowest 
effective dose in order to prevent rebound inflammation (Li, 2018). Li (2018) recommends 
topical ganciclovir 0.15% gel for effective management, even following a course of antivirals 
that had little effect. They conclude that further research is necessary to determine most effective 
treatments for HZO related ocular complications (Li, 2018). 
Optic neuritis affects 1.9% of HZO affected eyes (Vanikiete, et al., 2018). The 
pathophysiology of optic neuritis is not well understood, but one such theory is that the virus 
replicates on the ophthalmic branch of the trigeminal nerve, spreading to the orbit and causing 
direct injury to the optic nerve causing vision impairment (Vanikieti, et al., 2018). Treatment for 
optic neuritis is a combination of corticosteroids and acyclovir x 10 days to 2 months, depending 
on visual compromise (Vanikieti, et al., 2018). However, visual recovery two months after 
antiviral treatment is usually excellent (Vanikieti, et al., 2018).  
HZO can cause vascular and neural inflammation in its associated dermatome leading to 
arterial occlusion, or central retinal artery occlusion as a very rare complication of HZO (Ahmad, 
et al., 2019). Recommended treatment includes antivirals and steroids, with the use of IV 
acyclovir for severe HZO in these patients (Ahmad, et al., 2019).  
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One study by Grose (2018) found a correlation between HZO and risk for ischemic 
stroke: of 658 patients with HZO, 8.1% experienced an ischemic stroke within a year following 
their HZO diagnosis, compared to only 1.7% in those who did not have HZO. One week of 
antiviral treatment did not appear to reduce the risk of stroke, however the long-term antiviral 
treatment to reduce the risk of stroke has yet to be evaluated (Grose, 2018). The only known 
reduction of stroke risk related to HZO is prevention through herpes zoster vaccination, therefore 
preventing secondary stroke (Grose, 2018). 
Self-Management 
 Providing instructions for patients who will be caring for their disease at home will 
continue to promote healing, in addition to medication therapy. They may continue their usual 
daily activities as tolerated (Johnson, et al., 2015). Patients should be counseled to avoid contact 
with the immunocompromised, pregnant patients, and those who do not have a history of 
chickenpox infection or vaccination (Johnson, et al., 2015). Skin care can include wet-to-dry 
dressings to the herpes zoster lesions with saline or Burow’s solution for 30-60 minutes up to six 
times per day (Johnson, et al., 2015). Another topical option is calamine lotion for its antipruritic 
effect, although the therapeutic effect is not well supported by evidence (Johnson, et al., 2015). 
Proper education and instruction, in addition to medication management, can improve patient 
healing at home and aid in prevention of herpes zoster ophthalmicus associated symptoms.  
 
Conclusion 
• Herpes zoster ophthalmicus is the herpes zoster rash appearing along the V1 ophthalmic 
dermatome of the trigeminal nerve, affecting ocular and periocular structures, with 50% 
resulting in ocular complications. 
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• Vaccination against herpes zoster remains the pivotal method for preventing herpes 
zoster and HZO, and subsequently reducing HZO complications. 
• Treatment with an antiviral within 72 hours can significantly reduce the risk of HZO 
associated ocular complications. 
• Acyclovir, valacyclovir, and famciclovir are equally effective in the treatment of HZO. 
• Oral and topical corticosteroid treatment may aid in HZO associated pain and swelling, 
but should be prescribed under care of an ophthalmologist. 
• Consultation and referral with an ophthalmologist are essential for thorough 
ophthalmologic examination, management, and treatment of the patient with HZO, as 
many potentially severe ocular complications need specific attention. 
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